Literature DB >> 18369202

Interstitial lung disease in systemic sclerosis: a simple staging system.

Nicole S L Goh1, Sujal R Desai, Srihari Veeraraghavan, David M Hansell, Susan J Copley, Toby M Maher, Tamera J Corte, Clare R Sander, Jonathan Ratoff, Anand Devaraj, Gracijela Bozovic, Christopher P Denton, Carol M Black, Roland M du Bois, Athol U Wells.   

Abstract

RATIONALE: In interstitial lung disease complicating systemic sclerosis (SSc-ILD), the optimal prognostic use of baseline pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT) is uncertain.
OBJECTIVES: To construct a readily applicable prognostic algorithm in SSc-ILD, integrating PFTs and HRCT.
METHODS: The prognostic value of baseline PFT and HRCT variables was quantified in patients with SSc-ILD (n = 215) against survival and serial PFT data.
MEASUREMENTS AND MAIN RESULTS: Increasingly extensive disease on HRCT was a powerful predictor of mortality (P < 0.0005), with an optimal extent threshold of 20%. In patients with HRCT extent of 10-30% (termed indeterminate disease), an FVC threshold of 70% was an adequate prognostic substitute. On the basis of these observations, SSc-ILD was staged as limited disease (minimal disease on HRCT or, in indeterminate cases, FVC >or= 70%) or extensive disease (severe disease on HRCT or, in indeterminate cases, FVC < 70%). This system (hazards ratio [HR], 3.46; 95% confidence interval [CI], 2.19-5.46; P < 0.0005) was more discriminatory than an HRCT threshold of 20% (HR, 2.48; 95% CI, 1.57-3.92; P < 0.0005) or an FVC threshold of 70% (HR, 2.11; 95% CI, 1.34-3.32; P = 0.001). The system was evaluated by four trainees and four practitioners, with minimal and severe disease on HRCT defined as clearly < 20% or clearly > 20%, respectively, and the use of an FVC threshold of 70% in indeterminate cases. The staging system was predictive of mortality for all scorers, with prognostic separation higher for practitioners (HR, 3.39-3.82) than trainees (HR, 1.87-2.60).
CONCLUSIONS: An easily applicable limited/extensive staging system for SSc-ILD, based on combined evaluation with HRCT and PFTs, provides discriminatory prognostic information.

Entities:  

Mesh:

Year:  2008        PMID: 18369202     DOI: 10.1164/rccm.200706-877OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  258 in total

1.  How common is methotrexate pneumonitis? A large prospective study investigates.

Authors:  Navtej Sathi; Batsirai Chikura; Viswanath V Kaushik; Rose Wiswell; Julie K Dawson
Journal:  Clin Rheumatol       Date:  2011-06-03       Impact factor: 2.980

Review 2.  Evidence-based management of rapidly progressing systemic sclerosis.

Authors:  Dinesh Khanna; Christopher P Denton
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-06       Impact factor: 4.098

Review 3.  An update on the evaluation and management of pulmonary hypertension in scleroderma.

Authors:  John G Coghlan; Benjamin Schreiber; Benjamin Schrieber
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

4.  Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.

Authors:  P A Merkel; N P Silliman; P J Clements; C P Denton; D E Furst; M D Mayes; J E Pope; R P Polisson; J B Streisand; J R Seibold
Journal:  Arthritis Rheum       Date:  2012-10

Review 5.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

Review 6.  Interstitial lung disease in scleroderma.

Authors:  Sara R Schoenfeld; Flavia V Castelino
Journal:  Rheum Dis Clin North Am       Date:  2015-02-26       Impact factor: 2.670

7.  Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.

Authors:  Kimberly Showalter; Aileen Hoffmann; Gerald Rouleau; David Aaby; Jungwha Lee; Carrie Richardson; Jane Dematte; Rishi Agrawal; Rowland W Chang; Monique Hinchcliff
Journal:  J Rheumatol       Date:  2018-10-01       Impact factor: 4.666

Review 8.  Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.

Authors:  Karen Au; Dinesh Khanna; Philip J Clements; Daniel E Furst; Donald P Tashkin
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

Review 9.  [Systemic sclerosis. Objectives for the treatment].

Authors:  B Maurer; M Walder; R E Gay; S Gay; O Distler
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

Review 10.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.